Crinetics Pharmaceuticals, Inc. (CRNX) Tuesday announced positive results from Phase 3 PATHFNDR-2 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
PATHFNDR-2 was a randomized, double-blind, placebo-controlled 24-week treatment and the study met statistical significance on the primary endpoint. The company said all secondary endpoints also met statistical significance.
Paltusotine was generally well-tolerated and no serious adverse events were reported.
Acromegaly is a disorder in adults due to malfunctioning of the pituitary gland.
Crinetics intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.